Table 3.

Univariate and multivariate analysis of infliximab treatment failure

	Univariate Cox analysis HR (95% CI)	P	Multivariate Cox analysis HR (95% CI)	P
Proactive TDM	0.53 (0.28–0.97)	.042	0.51 (0.27–0.92)	.037
Sex (ref male)	1.02 (0.57–1.84)	.924	‐
Diagnosis (ref UC)	0.79 (0.42–1.50)	.477	‐
Perianal fistulizing disease	0.88 (0.43–1.83)	.734	‐
Age at diagnosis	1.02 (0.68–1.52)	.916	‐
Age at start of infliximab	1.33 (0.84–2.12)	.224	‐
CD localization (ref L1)	0.99 (0.69–1.44)	.978	‐
CD behaviour (ref B1)	0.91 (0.56–1.48)	.713	‐
UC extension (ref E1)	1.64 (0.60–0.79)	.182	‐
Concomitant use of immunomodulators	1.09 (0.54–2.20)	.806	‐
Extraintestinal manifestations	1.75 (0.98–3.13)	.057	1.72 (1.02–3.16)	.044

CD: Crohn's disease; CI: confidence interval; HR: hazard ratio; TDM: therapeutic drug monitoring; UC: ulcerative colitis.